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Abstract The primary pathology in mucopolysaccharidosis
(MPS) IIIB is lysosomal storage of heparan sulfate (HS)
glycosaminoglycans, leading to complex neuropathology
and dysfunction, for which the detailed mechanisms remain
unclear. Using antibodies that recognize specific HS glyco-
forms, we demonstrate differential cell-specific and
domain-specific lysosomal HS-GAG distribution in MPS
IIIB mouse brain. We also describe a novel neuron-specific
brain HS epitope with broad, non-specific increase in the
expression in all neurons in MPS IIIB mouse brain,
including cerebellar granule neurons, which do not exhibit
lysosomal storage pathology. This suggests that biosynthe-
sis of certain HS glycoforms is enhanced throughout the
CNS of MPS IIIB mice. Such a conclusion is further
supported by demonstration of increased expression of
multiple genes encoding enzymes essential in HS biosyn-
thesis, including HS sulfotransferases and epimerases, as
well as FGFs, for which HS serves as a co-receptor, in MPS
IIIB brain. These data suggest that lysosomal storage of HS
may lead to the increase in HS biosyntheses, which may
contribute to the neuropathology of MPS IIIB by exacer-
bating the lysosomal HS storage.
Keywords MPS IIIB.Lysosomal storage disease.Heparan
sulfate.Neuropathology.Glycobiosynthesis
Introduction
Heparan sulfates (HS) are a class of biologically important
glycosaminoglycans (GAGs) that serve as major functional
components of proteoglycans (PGs). Virtually every type of
animal cell has the capacity of HS biosynthesis. Heparan
sulfate proteoglycans (HSPGs) reside on the membrane of
all animal cells and in extracellular matrices and intracel-
lular components. HSPGs participate in various biological
processes as receptors or co-receptors for protein ligands,
including growth factors, cell adhesion molecules, morph-
ogens, cytokines/chemokines, enzymes/enzyme inhibitors,
and extracellular matrix proteins (Esko and Selleck 2002).
After ligand binding and signaling have occurred, most
transmembrane HSPGs are targeted for degradation by
endocytosis and subsequent transport to and degradation in
the lysosome (Freeze 2008; Varki et al. 2008). In the
lysosome, glycosidases remove individual monosaccharides
from the long GAG glycan chains. Monosaccharides are
then typically exported from the lysosome into the
cytoplasm to reenter new cycles of protein or lipid
glycosylation (Varki et al. 2008).
Mucopolysaccharidosis (MPS) IIIB is an inherited
lysosomal storage disease caused by the autosomal reces-
sive defect of α-N-acetylglucosaminidase (NaGlu) gene,
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DOI 10.1007/s11011-010-9230-xcoding for a lysosomal enzyme essential in the metabolic
degradation of HS-GAGs (Neufeld and Muenzer 2001).
Genetic mutations are highly heterogenic among patients
with MPS IIIB (Neufeld and Muenzer 2001;Y o g a l i n g a m
and Hopwood 2001). The lack of NaGlu activity disrupts
the stepwise enzymatic reaction for GAG degradation,
resulting in the accumulation of HS and HS-derived
oligosaccharides in lysosomes of cells in virtually all
organs, especially cells throughout the central nervous
system (CNS), including neuronal and non-neuronal cells,
although not all CNS cells are affected (Li et al. 1999).
Patients with MPS IIIB appear normal at birth, but
develop progressive and severe neurological disorder,
while somatic manifestations of MPS IIIB are relatively
mild compared to other types of MPS (Neufeld and
Muenzer 2001). The profound neurological manifestation
causes the high mortality in MPS IIIB patients. The
establishment of knock-out mouse model of MPS IIIB that
resembles the human disease has offered an invaluable
tool for studies on the disease mechanisms and therapeutic
development (Li et al. 1999).
No treatment is available for MPS IIIB. However, the
by-stander properties of lysosomal enzymes have led to the
success of recombinant enzyme replacement therapy and
hematopoietic stem cell transplantation which have been
used to treat patients with MPS I, II and VI, with somatic
benefits (Sands and Haskins 2008). MPS IIIB and other
lysosomal storage disorders with the CNS manifestations
are not amenable to enzyme replacement or stem cell
therapies because of the presence of the blood brain barrier
(BBB), which blocks entry of such therapies into the CNS.
Viral vector-mediated gene therapy approaches have been
developed for long-term restoration of the enzyme activities
in the CNS to treat the neurological disease of MPS IIIB
and other lysosomal storage disorders (Sands and Haskins
2008). While showing significant functional neurological
benefits, these gene therapy approaches did not yield a cure
in animal models of these diseases. Many studies have
shown that efficient expression of recombinant enzymes
leads to the reduction, but not the clearance, of lysosomal
storage pathology in animal models after therapeutic gene
delivery, despite high level expression of recombinant
enzyme activity (Cearley and Wolfe 2007; Cressant et al.
2004; Desmaris et al. 2004; Fu et al. 2002, 2007, 2010;
Heuer et al. 2002; Kurai et al. 2007; Liu et al. 2005;
McCarty et al. 2009; Sferra et al. 2000; Zheng et al. 2004).
These suggest that developing a cure for the CNS diseases
of MPS IIIB and other similar disorders may require more
than the simple restoration of the absent or deficient
lysosomal enzyme activity. This is supported by recent
studies demonstrating a complex multifactorial contribution
to the neuropathology of MPS IIIB, secondary to the
primary pathology- the lysosomal storage of HS and HS-
derived GAGs (DiRosario et al. 2009; Killedar et al. 2010;
Li et al. 2002; McGlynn et al. 2004; Ohmi et al. 2003,
2009; Ryazantsev et al. 2007; Villani et al. 2007; Walkley
2007). The complex neuropathology of MPS IIIB has been
shown to involve impaired metabolisms, inflammation,
neurodegeneration, reactive oxygen species and tauopathy.
A recent study reported the correlation between the high
efficiency of GAG synthesis and a severe phenotype in
patients with MPS, including MPS II, IIIA and IIIB
(Piotrowska et al. 2009). Further, strategies aimed at
reducing the accumulation of substrates for deficient
lysosomal enzymes, have shown therapeutic benefits or
potential in fibroblasts or mice with MPS IIIA, IIIB, by
inhibiting GAG synthesis using chemical inhibition or gene
silencing (Beck 2007; Dziedzic et al. 2010; Jakobkiewicz-
Banecka et al. 2009; Kaidonis et al. 2010; Malinowska et
al. 2009; Roberts et al. 2006, 2007). These data suggest that
the lysosomal storage pathology may induce the impair-
ment of glycosylation and/or GAG synthesis.
In this study we describe the accumulation of specific
HS glycoforms in the CNS of the MPS IIIB mouse model
and demonstrate differential distribution patterns of differ-
ent HS moieties. In addition, we demonstrate broad
increases in certain HS structures throughout MPS IIIB
brain, coupled with increased expression of HS biosynthetic
enzymes. These data suggest the importance of specific HS
glycoforms in the neuropathology of MPS IIIB and also
support a contributing role for elevated HS biosynthesis in
the disease.
Materials and methods
MPS IIIB mice
The MPS IIIB mouse model, generated by homologous
recombination (Li et al. 1999), was maintained on an inbred
background (C57BL/6) of backcrosses of heterozygotes. The
MPS IIIB mice resemble the human disease, have no
detectable NaGlu activity in any tissue, and exhibit charac-
teristic lysosomal storage pathology and clinical disorders.
The mice were housed in the Vivarium at the Research
Institute at Nationwide Children’s Hospital (NCH-RI). All
care and procedures were in accordance with the Guide for
the Care and Use of Laboratory Animals [DHHS Publication
No. (NIH) 85-23. The genotypes of progeny mice were
identified by PCR, using primers targeting mNaGlu Exon 6:
5’-TGGACCTGTTTGCTGAAAGC (sense) and 5’-
CAGGCCATCAAATCTGGTAC (anti-sense), or the trans-
gene (neomycin): 5’-TGGGATCGGCCATTGAACAA
(sense) and 5’-CCTTGAGCCTGGCGAACAGT (anti-
sense). Wild type (wt) littermates of MPS IIIB mice were
used as controls in all instances.
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For tissue sample collection, age-matched MPS IIIB and wt
mice were anesthetized with an intraperitoneal injection of
avertin (2.5%, 0.3–0.4 mg/g body weight), and were then
perfused transcardially with cold PBS (0.1 M, pH 7.4). The
entire brains of the mice were collected. Each brain was
divided into two halves along the midline, with each
hemisphere used for different assays. Tissue samples were
placed on dry ice or embedded in OCT compound and
stored at −70°C before being processed for analyses.
Anti-HS antibodies and immunohistochemical localization
of HS
The anti-HS antibodies used in this study (HS4E4, EV3C3,
HS4C3, AO4B08 and RB4Ea) were generated using the
phage display technology as described previously (van
Kuppevelt et al. 1998, 2001) and were selected for
reactivity against HS with different sulfation patterns,
which are summarized in Table 1 (Dennissen et al. 2002;
Kurup et al. 2007; Rops et al. 2008; Ten Dam et al. 2006).
These antibodies contain a vesicular stomatitis virus
Glycoprotein (VSV-G) tag for detection (van Kuppevelt et
al. 1998)]. An irrelevant antibody, MPB49, also contains a
VSV-G tag, was used as control (Lensen et al. 2005; Rops
et al. 2008).
Immunofluorescence was performed to probe HS on
coronal cryostat brain sections (10 μm). After the incuba-
tion in blocking buffer, PBS-TT (0.1% Tween-20, 0.1%
Triton-X-100, pH 7.4) containing 2% BSA, for 30 min at
room temperature, the sections were then incubated with
the above anti-HS antibodies (1:1 in blocking buffer)
overnight at 4°C. The sections were washed three times
with PBS-TT and then incubated with a mouse anti-VSV-G
monoclonal antibody (Sigma-Aldrich, V5507) diluted
1:200 in blocking buffer for 60 min at room temperature.
The bound antibodies were detected with a goat-anti-mouse
IgG conjugated with AlexaFluo568 (Invitrogen). Although
co-staining for neuronal and glial markers was not
performed, the sizes and morphological features of brain
parenchymal cells allowed us to determine the nature of the
involved brain cells. The intensity of the IF signals were
analyzed by manual thresholding using Image J software
(Abramoff et al. 2004).
Quantitative real time PCR
Total RNA was isolated from whole, dissected, brain hemi-
spheres using the SV Total RNA Isolation System (Promega),
following the manufacturer’s protocols. The isolated total
RNA samples were then further purified through an RNeasy
spin column (Qiagen). RNA content and quality was assessed
using a ND-1000 spectrophotometer.
Individual mouse brain total RNA samples were tested
by qRT-PCR for the expression of multiple genes involved
in HS biosynthesis, including N-deacetylase N-Sulfotrans-
ferase 1-4 (NDST1, 2, 3, 4), GlcA C5 Epimerase (GLCE),
fibroblast growth factor 1 and 2 (FGF-1 and FGF-2). The
sequence-specific primers were designed based on Entrez
gene sequences and the requirements of reagent suppliers
(Table 2). A pair of primers for murine GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) gene was used as
internal control. Superscript™ First-strand Synthesis Sys-
tem for RT-PCR (Invitrogen) was used for cDNA synthesis.
The qRT-PCR was performed using SYBR® Green PCR
Master Mix (Applied Biosystems). Comparative threshold
(CT) method was used for data analysis. Data were
expressed as relative quantitation of gene expression
(2^
−ΔΔCt) in the brain of MPS IIIB vs. wt mice (Livak and
Schmittgen 2001).
Protein isolation and Western blotting
Protein extraction and Western blotting were performed
following established procedures. Whole-cell proteins were
extracted from each whole mouse brain hemisphere
samples. Protein was measured using a modified Bradford
assay and identical amounts of whole cell protein were
loaded and separated by SDS-PAGE, and then immuno-
blotted after transfer onto nitrocellulose using a semi-dry
electrotransfer device (BioRad). The membranes were
probed using primary antibodies against FGF-1 (Santa
Table 1 HS modifications involved in antibody binding
Anti-HS antibodies HS modifications for antibody binding
HS4E4 N-sulfation
N-acetylation
C5-epimerization
HS4C3 N-sulfation
2-O-sulfation
6-O-sulfation
3-O-sulfation
EV3C3 N-sulfation
C5-epimerization
2-O-sulfation
AO4B08 N-sulfation
C5-epimerization
2-O-sulfation
6-O-sulfation
RB4EA12 N-acetylation
N-sulfation
6-O-sulfation
Metab Brain Dis (2011) 26:9–19 11Cruz) and FGF-2 (Upstate), followed by HRP-conjugated
secondary antibodies (Sigma), and developed with ECL
chemiluminiscent substrate (Pierce).
Results
Differential CNS distribution of HS glycoforms and cell-
specific HS accumulation in MPS IIIB mouse brain
Immunofluorescence detection using a panel of five anti-
HS antibodies (HS4E4, EV3C3, HS4C3, AO4B08,
RB4Ea) was performed on brain sections of adult MPS
IIIB mice and their age-matched wt littermates (6-month-
old, n=6/group), to determine the distribution of HS
containing different patterns of sulfation and their in-
volvement in the lysosomal storage pathology in the CNS
of MPS IIIB mice. These antibodies were obtained by
phage display technology and characterized by previous
studies as recognizing unique HS sulfation epitopes
(Dennissen et al. 2002; Kurup et al. 2007;t e nD a me ta l .
2003, 2004, 2006; Thompson and Nowakowski 1991;
Ulusoy et al. 2009; Valencia-Sanchez et al. 2006;V a l i u n a s
et al. 2005; van de Lest et al. 1994; van Kuppevelt et al.
1998, 2001;W i j n h o v e ne ta l .2008). These antibodies
bound differentially within the brains of the wt and MPS
IIIB mice (Table 3;F i g .1) and could be divided into two
major categories based on their binding patterns (Table 3).
The first group includes HS4E4, HS4C3, EV3C3 and
AO4B08, which bound brain parenchymal cells and/or
vasculature with differential intensity in wt versus MPS III
mice. The second category includes only RB4Ea12, which
exclusively stained brain parenchymal cells in both wt and
MPS IIIB mouse brains, including all neurons and glial
cells in white matter (Table 3,F i g .1). The reaction of each
antibody was observed throughout the brain, but with
distinct cell type specificities. No staining was detected in
the brains of either wt or MPS IIIB mice when using the
control antibody MPB49.
In wt mouse brain, both HS4E4 and HS4C3 reacted
with brain parenchymal cells in grey matter and
vasculature (Table 3;F i g .1a, b), while EV3C3 and
AO4B08 resulted in exclusive staining of blood vessels
without visible staining in other cells (Table 3;F i g .1a, b).
While there were intensity differences (Table 4), the
staining patterns of these four antibodies were relatively
homogenous in wt mouse brain. In contrast, in MPS IIIB
mouse, the staining with each of these antibodies was
generally coarse and substantially increased in both brain
cells and blood vessels (Table 3;F i g .1a–d). We observed
similar patterns of granulated staining by these four
antibodies in neurons in cerebral cortex, thalamus, brain
stem, and Purkinje cells (cerebellum) in MPS IIIB mouse
brains (Fig. 1a–d). These granulated patterns of staining
strongly suggest that these HS glycoforms, highly likely
HS oligosaccharides, accumulate within the lysosomes in
these cells. As such, HS glycoforms recognized by these
antibodies are likely to reflect membrane-bound cell
surface GAGs that are recycled through lysosomal path-
ways. Interestingly, none of these four antibodies reacted
to the HS in hippocampal neurons (Table 3,d a t an o t
shown), although hippocampal neurons are also known to
Table 2 Primer sequences for qRT-PCR
Gene symbols Gene names GeneBank accession # Primer sequences
NDST1 N-deacetylase/N-sulfotransferase 1 NM_008306 F: 5’-TGCTCTGTGTGATCTGAGGCTAG-3’
R: 5’-GATATCAAGCCCACAGCCAGAC-3’
NDST2 N-deacetylase/N-sulfotransferase 2 NM_010811 F: 5’-AAGTCTTAGAGCAGAACCCAC-3’
R: 5’-ACTATGGGAAAGAGATGGATC-3’
NDST3 N-deacetylase/N-sulfotransferase 3 NM_031186 F: 5’-AGCTAACAACCAAAGTCACAG-3’
R: 5’-CCTATCAGAGGCAAAAGGATG-3’
NDST4 N-deacetylase/N-sulfotransferase 4 NM_022565 F: 5’-ACCCTCTCTGGCAGCGAAATTG-3’
R: 5’-GTTCCCTGTTCCAGATAGGTAG-3’
GLCE glucuronyl C5-epimerase NM_033320 F: 5’-TGGTTTGGTTCACTTCTCTGAG-3’
R: 5’-AACTCCTAAAGGTCAAACCTGC-3’
FGF1 fibroblast growth factor 1 NM_010197 F: 5’-GAACCTCACCAAAAGCTTTCTC-3’
R: 5’-GTTTCTAATTTGCTGGGCACTTG-3’
FGF2 fibroblast growth factor 2 NM_008006 F: 5’-GAGTGTTTCTTCTTTGAACGAC-3’
R: 5’-GAGTTTATACTGCC AGTTCG-3’
GAPDH glyceraldehyde-3-phosphate dehydrogenase NM_008084 F: 5’-CACTGAAGGGCATCTTGGGCTACAC-3’
R: 5’-TTGGAGGCCATGTAGGCCATGAGGT-3’
The sizes of the qRT-PCR products are 105–120 bp
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indicating that the HS glycoforms in hippocampal
neurons may be unique relative to the HS structures
found in neurons in most other regions of the brain.
Further, we did not observe staining by any one of these
four antibodies in granular neurons in cerebellum
(Table 3;F i g .1), a group of neurons that do not exhibit
lysosomal storage pathology (Fu et al. 2007;L ie ta l .
1999). In white matter, such as corpus callosum, all four
antibodies bound only to the blood vessels, showing no
staining of neuronal axons or glial cells (Table 3;F i g .1a–
d). Blood vessel staining included both large blood vessels
(arteries and veins) as well as capillaries. As capillaries
lack smooth muscle, this suggests that blood vessel
staining was likely to be present in endothelial cells.
Blood vessel staining in MPS IIIB mouse brain was not
only increased but also displayed coarse (but not granu-
lated) features indicating pathologic changes in the
vasculature (Fig. 1a–d).
In contrast to the staining pattern using the other four
anti-HS antibodies, antibody RB4Ea exclusively stained
cells within the brain parenchymal, including both neurons
and glia, but not blood vessels. Although the intensity of
RB4Ea staining in the brain was significantly higher in
MPS IIIB mice than in wt mice (Fig. 1e; Table 4), it was
homogeneous in target cells, in contrast to the coarsely
punctuate patterns revealed by the other four antibodies.
The increase in RB4Ea staining was seen in all neurons,
including cerebella granular neurons, which, do not exhibit
lysosomal storage pathology. Taken together, these data
suggest that the increase of RB4Ea-specific HS glycoforms
in MPS IIIB mouse brain may not result from increased
lysosomal HS storage, since this antibody stains all
neurons, including neurons with or without lysosomal
storage pathology, in a pattern inconsistent with the
presence of lysosomal GAG accumulation. It is therefore
likely that this elevated HS expression results from specific
changes in HS biosynthesis.
Elevated expression of genes encoding HS synthetic
enzymes and FGFs in MPS IIIB brain
The distribution and increased expression of HS glyco-
forms in MPS IIIB mouse brain suggested that HS
synthesis may be elevated, in addition to increased
lysosomal storage of HS GAGs. To further assess HS
biosynthesis, we performed qRT-PCR using the total RNA
isolated from 1-month-old and 6-month-old mice (n≥4/
group), targeting multiple genes that encode enzymes
involved in synthesis of specific HS glycoforms, including
Table 3 Differential anti-HS antibodies binding in mouse brain
Brain cells LS-path HS4E4 HS4C3 EV3C3 AO4B08 RB4Ea12
wt IIIB wt IIIB wt IIIB wt IIIB wt IIIB
Endothelia ± +++ ++++ + ≥ ++ ++ ≥ +++ ++ ++++ ––
Neurons + ++++ + ≥ +++ – ++++ – ++++ ++ ++++
CTX
aY+
e++++ +
d++++ –
d++++ –
d++++ ++ ++++
TH
bY+
e++++ +
e++++ –
e++++ –
e++++ ++ ++++
HP
bY – – –– –– –– ++ ++++
BS-M
cY+
d++++ +
f++++ –
e++++ –
e,f++++ ++ ++++
BS-I
b,cY+
e+++
e++++
e++++
e,f++++ ++ ++++
CB-P
cY+
f+++ +
f++++ –
d++++ –
f++++ ++ ++++
CB-G N – – –– –– –– ++ ++++
WM-glia n/a – – –– –– –– ++ ++++
Cryostat brain sections from wt (n=4) and MPS IIIB (n=4) mice were assayed for HS domains by immunofluorescence (IF) staining. LS-Path
lysosomal storage pathology, CTX cerebral cortex, TH thalamus, HP hippocampus, BS-M ventral medullary retic nuclear of brain stem, BS-I
Intermediate reticular nuclei of brain stem, CB-P cerebellum-Purkinje cells, CB-G cerebellum-granular neurons, WM white matters. Lysosomal
storage pathology by toluidine blue staining: ±: Majority endothelial cells do not exhibit lysosomal storage pathology; Y exhibiting lysosomal
storage pathology, N no visible lysosomal storage pathology.+–++++: relative IF staining intensities observed under a fluorescent microscope,
referring the intensity of HS4C3 stained wt endothelia and HS4E4 stained wt brain cells as +
aFine foamy vesicles
bSmall vacuoles
cLarge vacuoles
Anti-HS antibody staining:
dFine granules
eSmall granules
fCoarse granules
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Fig. 1 Differential distribution of HS domains in the brains of wt and
MPS IIIB mice. Cryostat brain sections (10 μm) of 6-month-old wt and
MPS IIIB mice were stained by immunofluorescence for specific HS
domains using five antibodies targeting HS epitopes with different
sulfation patterns: a HS4E4, b HS4C3, c EV3C3, d AO4B08, e RB4Ea.
f MPB49 control. +/+ wt; -/- MPS IIIB, BS brain stem; CB cerebellum,
TH thalamus, HP hippocampus. Yellow arrowheads: HS+ neurons. Blue
arrows HS+ vasculature. G granular layer, M molecular layer; Purkinje
cell layer (between two white lines). Scale bars: 20 μm
14 Metab Brain Dis (2011) 26:9–19NDST1-4 and GLCE, and the end product markers of
GAG function, such as FGF1 and FGF2 (Table 5). We
found a moderate but significant increase (P<0.05) in
most HS synthesis-related transcripts tested in whole MPS
IIIB brain (compared to wt), with the exception of FGF1,
at 1 month and 6 months of age (Table 5). Western blot
probing FGF1 and FGF2 was carried out to further assess
whether the disease alters the expression of these growth
factor in the brain of 6-month-old mice, and showed a
significant increase in both FGF1 and FGF2 proteins in
MPS IIIB brain (Fig. 2). These results support our
hypothesis that the lysosomal HS storage led to the
elevation of HS biosynthesis and elevated HS and FGF
expression, which may, in turn, exacerbate lysosomal
storage pathology. It is important to note that many factors
can be attributed to the disparity between FGF 1 mRNA
and protein, such as the property of the primers used for
qRT-PCR.
Discussion
While the accumulated GAGs in MPS disorders are well-
described, it is unclear in most instances whether lack of
lysosomal degradation leads to equivalent build-up of all
glycan structures within a particular group or whether
specific glycans preferentially accumulate in the lysosome.
Moreover, while lack of glycan degradation clearly drives
these diseases, possible compensatory up-regulation of
biosynthesis, resulting from loss of glycan functions, could
contribute to overall glycan burden and disease severity.
Determining the relevance of these two issues is essential to
determining whether therapies in addition to enzyme
replacement would be of benefit in lysosomal storage
disorders. Here we have used five anti-HS antibodies, each
recognizing unique repertoire of different HS sulfation
domains, to demonstrate for the first time a cell-type-
specific and domain-specific distribution pattern of lyso-
somal HS storage in the CNS of MPS IIIB mice. It has been
reported that the tissue distribution of HS sulfation epitopes
is highly defined and tightly regulated (Dennissen et al.
2002). For example, in skeletal muscle a specific HS form,
recognized by antibody RB4EA, is concentrated at the
neuromuscular synapse while others are present throughout
+/+           -/-
1        2       3        4        5       6
FGF-2
β β-actin 41.7kD
17kD
FGF-1 15.5kD
Fig. 2 Increase in the expression of FGF1 and FGF2 in MPS IIIB
mouse brain. Whole cell proteins (20 μg/sample) isolated from the
brain of 6-month-old mice were subjected to SDS-PAGE separation
and western blotting for FGF1, FGF2, or beta actin control. FGF2. +/+
1–3: wt (n=3); -/- 4–6: MPS IIIB (n=3)
Table 4 Quantification of the increases in specific HS glycoforms in MPS IIIB mouse brain cells
Mice IF intensity (grey value)
HS4E4 HS4C3 EV3C3 AO4B08 RB4Ea
BS CB BS TH BS CB BS CB HP CB
+/+ 130±8 101±7 105±16 105±7 134±20 131±10 n/a 122±19 122±14 149±25
−/− 168±19 248±5 238±10 247±4 236±26 248±3 248±4 249±3 245±2 246±5
Quantitative analysis of IF images in Fig. 1. All non-vasculature IF signals were analyzed by manual thresholding using Image J software. Data
here are the means±SD/unit (cell)
+/+ wt, −/− MPS IIIB, BS brain stem, CB cerebellum, TH thalamus, HP hippocampus, n/a no non-vasculature IF signal. IF intensity was
significant between all compared groups (P<0.01)
Table 5 Elevated expression of genes essential for HS biosynthesis in
MPS IIIB mouse brains
Genes
a2
-ΔΔCt (fold of increase)
b1m o
b6m o
NDST1 1.1
c1.7
NDST2
c1.4
c1.8
NDST3
c1.7
c2.1
NDST4
c2.0
c1.6
GLCE
c1.4
c1.7
FGF1 0.9 1.0
FGF2
c1.5
c1.3
aqRT-PCR data was analyzes by means of the comparative threshold (Ct)
method and expressed as 2
-ΔΔCt (fold of increase), relative quantitation of
gene expression in the brain of MPS IIIB mice (n=5) vs. wt mice (n=4)
bThe age of mice tested
cThe increases in gene expressions are significant (P<0.05, ΔCt-MPS IIIB
vs. ΔCt-wt)
Metab Brain Dis (2011) 26:9–19 15the muscle membrane (Jenniskens et al. 2002). Similarly,
some antibodies to certain HS glycoforms stain the
glomerular basement membrane of the kidney (HS4C3)
but not the tubules (van Kuppevelt et al. 1998), while
others (EV3C3) specifically stain the epithelial cells of
lung bronchioli (Smits et al. 2004). Thus, each of the
antibodies we have used shows specific tissue staining
patterns and a specificity for binding to HS glycoforms.
Consistent with this, our data reveals different intracellular
and cell-type specific distribution patterns of HS domains,
and that the same cell types can harbor multiple types of
HS domains. Our data lead to two important findings.
First, we have demonstrated the neuronal specificity of
cell surface HS domains in mice. Second, we have found
that the lysosomal HS storage may cause an increase in
HS biosynthesis in MPS IIIB mouse brain, which may be
an important factor that, in turn, exacerbates the HS
accumulation.
Four of these five antibodies, HS4E4, HS4C3, EV3C3
and AO4B08, were shown to recognize HS in brain cells
(predominantly neurons) and/or brain vasculature of both
wt and MPS IIIB mice. The HS domains reacting with
these antibodies are distributed homogenously in the CNS
and blood vessel cells of the wt mouse brain. In contrast, in
MPS IIIB mouse brain, these HS epitopes are quantitatively
increased in neurons, with coarse and/or granulated
distribution patterns correlating with the patterns of CNS
lysosomal storage pathology in these animals. It is therefore
highly likely that in these neurons the HS domains
recognized by HS4E4, HS4C3, EV3C3 and AO4B08 are
membrane-bound cell surface GAGs, which normally
recycle through lysosomes, and the increase in these HS
epitopes in the CNS of MPS IIIB mice may be predomi-
nately due to the accumulation of undegraded or partially
degraded HS GAGs in lysosomes of brain cells. Given the
broad specificity of these antibodies for particular HS
glycoforms, the relative uniform change in MPS IIIB brain
staining for all four of these antibodies suggests that HS
forms with 2-O-, 3-O-, and 6-O-sulfation and also
N-sulfated glucuronic acid accumulate in lysosomes in
neurons. This conclusion is supported by the observation
that none of these four antibodies reacted with HS in
granular neurons in the cerebellum, which are a group of
neurons that do not exhibit lysosomal storage pathology in
MPS IIIB mice (Fu et al. 2007; Li et al. 1999). These data
may be important for the further characterization of the
nature and functional significance of neuronal surface
HSPGs in the CNS. The specific HS domains may also
have potential as therapeutic targets for MPS IIIB.
Interestingly, while each of these four antibodies reacts
with HS in the same cell-types between normal and MPS
IIIB mouse brain, we observed Ab-specific lysosomal
distribution patterns in MPS IIIB mouse brains, suggesting
HS domain-specific degradation pathways involving differ-
ential lysosomal trafficking.
While the increased abundance and aberrant distribution
of HS domains targeted by HS4E4, HS4C3, EV3C3 and
AO4B08 occurs in the majority of neurons having
lysosomal storage pathology, none of them recognized HS
in hippocampal neurons, which are also known to manifest
lysosomal storage pathology (unpublished data). The
absence of these domains from this particular neuronal cell
type is likely to be related to its function, and further
studies in models such as this could provide a reliable
method of associating different HS domains with specific
cell-types in situ, which may advance our understanding of
the roles of HSPG in neuronal functions. Further, these
antibodies may be used to screen the stored specific HS
domains in MPS IIIB and other types MPS III disorders
that also manifest lysosomal HS storage as therapeutic
targets for these diseases.
We also observed that HS4E4, HS4C3, EV3C3 and
AO4B08 recognize the HS domains in both large blood
vessels and capillaries in the brains of wt and MPS IIIB
mice, although with increased intensity in the mutant
animals. Previous studies showed that HS is found in the
basement membrane of all vasculature and that these four
antibodies bind to blood vessels in other organs (Dennissen
et al. 2002; van Kuppevelt et al. 1998). Because endothelial
cells are the sole constituents of capillary walls in somatic
tissues, it is highly likely that the HS epitopes recognized
by these four antibodies are normally harbored in endothe-
lial cells. It is worth noting that majority of endothelial cells
in MPS IIIB mouse brain do not manifest lysosomal storage
pathology. Therefore, it is likely that HS4E4, HS4C3,
EV3C3 and AO4B08-bound HS epitopes in the vascula-
tures are not GAGs recycled through lysosomal pathways,
and the substantial increase of these HS epitopes in the
CNS endothelial cells in MPS IIIB mouse brain may not be
the consequence of lysosomal HS storage. These data also
imply the functional-specificity of these HS glycoforms in
different cell types.
While each of the four Abs discussed above revealed a
coarse punctuate distribution of HS domains in neurons,
consistent with lysosomal accumulation, the distinctly
homogeneous cytoplasmic HS recognition pattern of
antibody RB4Ea led to our hypothesis that the lysosomal
HS accumulation may have secondary pathological impacts
on glycosylation in the CNS of MPS IIIB mice. This
antibody reacts exclusively with the HS domains in brain
parenchymal cells, including all neurons and glia, but not
vascular cells. That this antibody does not stain blood
vessels has been previously reported in skeletal muscle,
where it is concentrated specifically at the neuromuscular
synapse and in intramuscular nerves (Jenniskens et al.
2000). The increase in RB4Ea staining in MPS IIIB mouse
16 Metab Brain Dis (2011) 26:9–19brain is homogenous in all of its target cells, including
granular neurons in cerebellum, and this increased staining
does not show patterns consistent with lysosomal storage
pathology. While the exact natures of the HS epitopes these
different antibodies bind to remain unclear, previous studies
showed that the antibody-binding HS epitopes are likely to
be complex of specific modifications (Dennissen et al.
2002; Kurup et al. 2007; Smits et al. 2006; Ten Dam et al.
2006). It is possible that RB4Ea12 binds preferentially to
HS forms that may not be present as a trans-membrane
GAGs on cell surfaces. This raises the question as to why it
is over-represented in MPS IIIB brain cells, since it does
not appear to depend on lysosomal degradation. We
hypothesized that the elevation of RB4Ea, unlike elevation
of glycoforms recognized by other four HS antibodies, is
likely a consequence of enhanced HS biosynthesis, and this
is supported by the up-regulation of multiple enzyme genes
essential for HS biosynthesis, such as NDST1-4 and GLCE,
as well as an increase in the expression of FGF1 and FGF2
in MPS IIIB mouse brain. Based on these findings, we
suggest that the observed increase in HS biosynthesis is a
compensatory response to the disruption of normal HS
recycling in MPS IIIB cells. Once broken down in
functional lysosomes, individual units of HS monosacchar-
ides are typically transported from the lysosomal compart-
ment into the cytoplasm, and reused in biosynthetic
glycosylation pathways (Varki et al. 2008) In MPS IIIB
mouse brain, the lysosomal storage of HS results in a
shortage of HS to be reused for glycosylation, which then
leads to the enhanced HS biosynthesis to compensate for
such effects. Because we observed up-regulation of an HS
moiety that was not lysosomal, we believe that the increase
is non-preferential, possibly involving not only membrane-
bound cell surface HS domains, but also intracellular and
extra-cellular matrix HS epitopes. This is supported by the
increase in HS4E4, HS4C3, EV3C3 and AO4B08-bound
HS domains in endothelial cells in MPS IIIB mouse brain,
while majority endothelial cells do not exhibit lysosomal
HS storage pathology. Importantly, we have also demon-
strated that the elevation of HS biosynthesis emerges early
in the brain of MPS IIIB mice. Hence, it is highly likely to
contribute to the neuropathology of the disease by
exacerbating the lysosomal HS accumulation, which is
supported by the report that high efficiency of GAG
synthesis leads to a severe phenotype in patients with
MPS IIIB, IIIA and II (Piotrowska et al. 2009). These HS
biosynthesis pathways may therefore offer a specific target
for MPS IIIB therapeutic development, by inhibiting the
HS biosynthesis using small molecules as demonstrated in
recent studies using rhodamine B in mice with MPS IIIA,
another disease with lysosomal HS storage (Roberts et al.
2007; Roberts et al. 2006), or by gene silencing as shown in
two most recent in vitro studies for MPS IIIA and MPS I
(Dziedzic et al. 2010;K a i d o n i se ta l .2010). This hypothesis
is also supported by recent studies showing that genistein, a
GAG synthesis inhibiting soy extract, can reduce lysosomal
storage in vitro in MPS cell cultures (Jakobkiewicz-Banecka
et al. 2009) and in MPS IIIB mice (Malinowska et al. 2009).
In summary, this is the first report of cell-specific
and domain-specific lysosomal storage of HS in MPS
IIIB mouse brains, and has led to the finding that the
subsets of membrane-bound cell surface HS epitopes
are neuronal type-specific in the CNS. We also
demonstrated that lysosomal HS storage results in the
increased expression of genes of multiple enzymes
involved in HS biosynthesis in the CNS, which emerges
early during disease progression, which may exacerbate
the lysosomal storage pathology of MPS IIIB. These
data may contribute substantially to mechanistic studies
on the functions of specific HS domains in the CNS
cells, leading to a better understanding of HS function
and to the neuropathology of MPS IIIB, offering new
potential targets for therapeutic development for MPS
IIIB neuropathology.
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